HOME >> MEDICINE >> NEWS
First medication to target PCP addiction is reported by Arkansas researchers

Animal studies by researchers at the University of Arkansas for Medical Sciences (UAMS) used an antibody-based drug to provide immediate protection against the chronic abuse of phencyclidine (PCP). The studies mark the first time that a long-acting treatment has been developed to block or reduce the psychoactive effects of PCP in drug addicts, according to UAMS scientist S. Michael Owens, Ph.D. In earlier studies, he used a smaller fragment of the antibody to treat drug overdose.

Owens presented his findings here today at the national meeting of the American Chemical Society, the world's largest scientific society.

Owens said his new technique uses monoclonal antibodies-identical copies of animal antibodies cloned and reproduced in the laboratory-to prevent or slow the entry of PCP into the brain, where it produces its pleasurable effects. The ability to create huge quantities of these antibodies makes it possible to administer a very large dose in a single injection. In the animal studies, just one injection curbed the effects of PCP for at least two weeks-a period equivalent to one to two months in humans, Owens said.

This fast-acting therapy could make a profound difference in the way PCP addicts are treated, enabling doctors to offer addicts an effective anti-addiction medication that works immediately. By contrast, antibody-based approaches to creating vaccines entail weeks of waiting before benefits appear, Owens said.

PCP triggers hallucinations, psychotic behavior, violence, and even self-destruction.

In a 1997 NIDA survey of high school seniors, more than two percent of the students said they had used PCP in the preceding 30 days. "Young people are attracted to PCP even though they know how dangerous it is, because it is inexpensive and because it produces euphoria, hallucinations and a feeling of superhuman strength," said Owens.

The UAMS research is supported by grants from the National Institute for Drug Ab
'"/>

Contact: Charmayne Marsh
y_marsh@acs.org
202-872-4445
American Chemical Society
24-Aug-1999


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
(Date:10/22/2014)... For Dr. Iris Hunter, a job is more than just ... life’s mission. Her extensive experience in the nonprofit sector, coupled ... make it clear that Hunter’s mission is to serve others. ... a difference in the lives of others,” Hunter said. “Additionally, ... I felt ready to start on this journey as a ...
(Date:10/22/2014)... 2014 Hay House is pleased to announce ... Upgrade Your Life (Paperback; $10.82) written by the highly esteemed ... This book is meant to help readers of all ... recovery. , Recovery 2.0 is not the average self-help ... is a guide for what comes next. For ...
(Date:10/22/2014)... Your Body’s Way , In a world where a multi-billion-dollar ... can be difficult to choose the right weight loss method. ... it the healthy way? Set aside the fads and resist ... regularly, and choose foods with the most nutritional benefits. ... exercise more and eat less. Despite the number of advertisements ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... who quickly add weight and length may be showing a ... In adults, certain genes have been linked to increased ... gains in fat and lean muscle, the researchers said. ... and taller. By ages 2 and 3, however, these genes ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
(Date:10/22/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... focused on the development of oral drug delivery ... its Phase IIa clinical trial of ORMD-0801, the ... 1 diabetes. The trial was conducted in ... Food and Drug Administration (FDA) Investigational New Drug ...
(Date:10/22/2014)... ANAHEIM, Calif. , Oct. 21, 2014 Influenza ... with flu-associated deaths in the United States ... influenza viruses are thought to spread is from person to ... Ebola has a serve way of death, but kills ... of Ebola is also done by human fluids including sweat, ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 WHEN: ... EDTLOCATION: Online, complimentary registration available at: ... Leader Archana Vidyasekar and Visionary Innovation Research ... WiFi-like wireless electricity, self-assembling materials, nanobots and ... technologies which will transform our lives in ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
Cached News: